Review Article
Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy
Table 3
Reported adverse effects of mTOR inhibitors.
| General disorder classification | Specific adverse event | Reported percent incidence | Duration on Meds (days) | Agent | Clinical management options | Outcome |
| Cutaneous | Delayed wound healing | | | Multiple mTOR inhibitors | | Manageable | | Skin rash | | | Ridaforolimus | | Manageable | | Spongiotic dermatitis with eosinophils | | 14 | Temsirolimus | Clobetasol | Resolution | Hematological | Thrombocytopenia | 8–22.7 | | Everolimus and sirolimus | Interleukin 11 | Manageable | | Anemia (microcytic) | 9–20 | | Temsirolimus and everolimus and sirolimus | Erythropoietin | Manageable | | Leukopenia | 18.2 | | Everolimus and sirolimus | Colony stimulating factor | Manageable | Hepatic | Transaminase Elevations | 10 | | Everolimus | Periodic liver function tests | | | Alkaline phosphatase elevations | 8 | | Everolimus | Periodic liver function tests | | Immunological | Severe infections | 2.3 | | | | | Metabolic | Hypercholesterolemia | 50 | | Sirolimus and everolimus | Statin therapy | Manageable | | Hypertriglyceridemia | 31.8 | | Sirolimus and everolimus | Fibrates | Manageable | | Hyperglycemia | 11 | | temsirolimus | Glucose lowering agents | Manageable | | Fatigue | 11 | | Temsirolimus | | | | Hypophosphatemia | 5 | | Temsirolimus | | | | Hyperlipidemia | 5 | | Everolimus | Lipid lovering drugs | | Oral | Ulcerations | 66 | 5 | Deforolimus | Discontinuation | Reversible | | Mucositis | 6 | | | Discontinuation | Reversible | | Aphthous stomatitis | 6 | | | Discontinuation | Reversible | Pulmonary | Noninfectious pneumonitis | 4.8–18 | 60–1500 | Sirolimus and everolimus | Withdrawal, antibiotics and steroids | Reversible | | Dyspnea | 9 | | | | | | Grade 1 (asymptomatic) | 3.3 | | Everolimus | Reduction | Reversible | | Grade 2 (Ok daily living) | 6.6 | | Everolimus | Withdrawal | Reversible | | Grade 3 ( oxygen indicated) | 3.6 | | Everolimus | Withdrawal, antibiotics and steroids | Reversible | | Grade 4 (life threatening) | 0 | | Everolimus | None | | Renal | Proteinuria | 1.6–4.1 | 540–1500 | Sirolimus and everolimus | Withdrawal | Reversible | | Proteinuria (grade 3 to 4) | 25 | 273 | Bevacizumab + everolimus | Discontinuation | Reversible | Reproductive | Infertility (oligospermia) | 66.6 | 150–360 | Sirolimus | Discontinuation | Full recovery | | amenorrhea | 14.2 | 150–360 | Sirolimus | Discontinuation | Reversible |
|
|